The global plasmid DNA manufacturing market, valued at USD 317 million in 2025, is projected to reach USD 395 million in 2026 and USD 2,689 million by 2035, representing a CAGR of 23.74% during the forecast period 2026 to 2035. The success of plasmid-based platforms during the COVID-19 pandemic (used by companies like Moderna and Pfizer-BioNTech) highlighted their importance in rapid vaccine development. This has driven sustained demand for plasmid DNA in DNA / RNA vaccines, infectious disease r...

The Europe peptide synthesis market, valued at USD 1.5 billion in 2025, is projected to reach USD 1.7 billion in 2026 and USD 2.7 billion by 2035, with a CAGR of 5.3% during the forecast period from 2026 to 2035. The rapid uptake of peptide-based treatments for obesity and type 2 diabetes is substantially increasing demand for clinical- and commercial-scale peptide synthesis in Europe. In fact, PolyPeptide reported that metabolic products represented 57% of its revenue in 2025. In July 2026, Bac...

The global advanced wound care market, valued at USD 13.10 billion in 2025, is projected to reach USD 13.86 billion in 2026 and USD 23.45 billion by 2035, representing a CAGR of 6.02% during the forecast period 2026 to 2035. In May 2026, Smith+Nephew announced the launch of two new wound care innovations, including ALLEVYN® COMPLETE CARE Foam Dressing and RENASYS® EDGE Negative Pressure Wound Therapy System to simplify wound management and reduce the associated clinical burden. In June 2026, H...

The Asia-Pacific liquid biopsy market, valued at USD 1.8 billion in 2025, is projected to reach USD 2.0 billion in 2026 and USD 8.6 billion by 2035, representing a CAGR of 17.6% during the forecast period 2026 to 2035. India is also emerging as an important market for liquid biopsy. In July 2026, Zydus Lifesciences entered into an exclusive agreement with Guardant Health to make the Shield Multi-Cancer Detection test available in India and signed a memorandum of understanding (MoU) with Apollo H...

The Asia-Pacific medical device contract manufacturing market, valued at USD 17.3 billion in 2025, is projected to reach USD 18.9 billion in 2026 and USD 38.1 billion by 2035, with a CAGR of 8.1% during the forecast period from 2026 to 2035. The region includes a growing network of contract manufacturers serving complex medical device categories, including minimally invasive devices, diagnostic equipment, cardiovascular products, orthopedic implants, diabetes care solutions, wearable medical dev...

The global dental 3D printing market, valued at USD 3.9 billion in 2025, is projected to reach USD 4.9 billion in 2026 and USD 17.6 billion by 2035, with a CAGR of 15.3% during the forecast period 2026-2035. 3D printing, also known as additive manufacturing, is a method of producing 3-dimensional objects layer-by-layer, using a computer aided design. Owing to its ability to print complex models using a wide range of materials, 3D printing has applications across various industries, including den...

The global electronic health records market, valued at USD 41 billion in 2025, is projected to reach USD 45 billion in 2026 and USD 92 billion by 2035, representing a CAGR of 8.3% during the forecast period from 2026 to 2035. Healthcare delivery is becoming increasingly data-driven, and electronic health records (EHR) have emerged as the digital backbone of this transformation. Modern EHR platforms are no longer limited to replacing paper charts; they serve as centralized clinical information sy...

The global rare kidney diseases market size, valued at USD 3.4 billion in 2025, is projected to reach USD 4.9 billion in 2026 and USD 21.7 billion by 2040, with a CAGR of 11.2% during the forecast period 2026 to 2040. According to the Orphan Drug Act, in the United States, diseases are considered rare when they affect less than 200,000 Americans. However, according to the European Union, the prevalence threshold is 5 per 10,000 people. In June 2026, AstraZeneca received Priority Review designati...

The global single-use bioprocessing equipment market, valued at USD 4.2 billion in 2025, is projected to reach USD 4.5 billion in 2026 and USD 9.5 billion by 2035, representing a CAGR of 8.7% during the forecast period from 2026 to 2035. Each biologic entering clinical or commercial production requires cell-culture, filtration, fluid-transfer and storage infrastructure. In 2025, the European Medicines Agency recommended 104 medicines for authorization, including 38 products with new active subst...

The global cancer therapeutics market, valued at USD 190.6 billion in 2025, is projected to reach USD 232.2 billion in 2026 and USD 516.2 billion by 2035, representing a CAGR of 9.3% during the forecast period 2026 to 2035. Cancer remains a major clinical and economic challenge despite continuous advances in early detection and treatment. The American Cancer Society projects that approximately 2,114,850 new cancer cases and 626,140 cancer deaths will occur in the United States in 2026. In July 2...

The global serum-free media market, valued at USD 2.3 billion in 2025, is projected to reach USD 2.5 billion in 2026 and USD 4.6 billion by 2035, representing a CAGR of 7.2% during the forecast period from 2026 to 2035. This widespread integration is directly propelled by the rapid influx of complex biologics advancing through clinical and commercial pipelines. With the US Food and Drug Administration approving 12 novel biologics and 18 biosimilars in 2025, biomanufacturers face a strict mandate...

The global Dry Age-Related Macular Degeneration market reached USD 5.3 billion in 2026 and is projected to reach USD 14.9 billion by 2040, growing at a CAGR of 7.66% over the forecast period 2026 to 2040, driven by geographic atrophy therapy uptake, PBM adoption, and AI monitoring. Based on Geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 9.8% CAGR through 2040, supported by Japan and China access expansion. Approved GA therapies now pull revenue tow...

The global Smart Hospitals market is expected to rise from USD 15 billion in 2026 to reach USD 160 billion by 2040, growing at a CAGR of 18.4% over the forecast period 2026 to 2040, driven by rise in connected inpatient-room modernization. Based on technology / integration layer, EHR-integrated room systems capture 24.0% market share in 2026, whereas AI and computer vision analytics register a 24.4% CAGR through 2040, driven by real-time sensing and autonomous clinical documentation. Based on ap...

The global antibody discovery market, valued at $2.0 billion in 2025, is projected to reach $2.2 billion in 2026 and $6.3 billion by 2035, representing a CAGR of 12.3% during the forecast period 2026 to 2035. This market includes the opportunity for antibody discovery service and technologies / platform providers across the full discovery workflow, from target identification and hit generation through lead selection, lead optimization, and preclinical validation. Oncological disorders account fo...

The global antibody drug conjugate market, valued at USD 15.29 billion in 2025, is projected to reach USD 18.69 billion in 2026 and USD 28.41 billion by 2035, representing a CAGR of 4.8% from 2026 to 2035. Breast Cancer therapies currently account for 44.7% of the antibody drug conjugate (ADC) market, supported by the large treated population, established HER-2-targeted products, and sustained development. The lung cancer segment will likely grow at a higher CAGR and occupy a larger market share...

The global ADC contract manufacturing market, valued at USD 1,720 million in 2025, is projected to reach USD 2,138 million in 2026 and USD 3,212 million by 2035, representing a CAGR of 4.6% during the forecast period. An expanding oncology pipeline of over 600 ADC candidates and 28 approved ADC therapeutic programs is increasing demand for outsourced bioconjugation, cGMP manufacturing, high-potency handling, and commercial-scale supply. Antibody manufacturing dominates the current market by proc...

The global insulin pump market, valued at USD 6.1 billion in 2025, is projected to reach USD 6.5 billion in 2026 and USD 13.6 billion by 2035, representing a CAGR of 8.5% during the forecast period 2026 to 2035. In terms of type of pump, the patch pumps segment holds the highest (more than 60%) share of the current market. The emergence of automated insulin delivery systems represents a defining shift in the domain. These platforms use real-time glucose data and algorithms to adjust insulin deli...

The global inflammatory bowel disease treatment market size, valued at USD 22.6 billion in 2025, is projected to reach USD 24.3 billion in 2026 and USD 43.8 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. Close to 30 drugs are currently approved for the treatment of inflammatory bowel disease. However, these drugs often fail to achieve sustained remission in a significant subset of patients and frequently lose effectiveness over time. Many drugs are associat...

The global plant-based meat market, valued at USD 18.7 billion in 2025, is projected to reach USD 20.6 billion in 2026 and USD 54.8 billion by 2035, representing a CAGR of 11.5% during the forecast period 2026 to 2035. In terms of source of protein, soy protein holds the largest share, accounting for approximately 45% of the current plant-based meat market.

The global primary cells market, valued at USD 1.19 billion in 2025, is projected to reach USD 1.26 billion in 2026 and USD 2.04 billion by 2035, representing a CAGR of 5.5% during the forecast period 2026 to 2035. In terms of source of origin, cells sourced from humans hold the highest share (nearly 75%) of the current market. With respect to type of organ system, cells sourced from the nervous system dominate the current market. Based on the type of primary cells, fibroblasts account for the l...